Companion Diagnostics Market to Reach USD 6.51 Billion by 2022

03:39 EDT 1 Aug 2017 | PR Newswire

PUNE, India, August 1, 2017 /PRNewswire/ --

According to a new market research report "Companion Diagnostics Market by Technology (PCR, IHC, NGS, ISH), Indication (Breast cancer, NSCLC, Colorectal cancer, Neurological disorders, Infectious Diseases), End User (Pharmaceutical & Biopharmaceutical Companies, Reference Lab) - Global Forecast to 2022", published by MarketsandMarkets™, the Companion Diagnostic Market is expected to reach USD 6.51 Billion by 2022 from USD 2.61 Billion in 2017, at a CAGR of 20.1%. 

     (Logo: )

Browse 105 market data Tables and 37 Figures spread through 170 Pages and in-depth TOC on "Companion Diagnostics Market"
Early buyers will receive 10% customization on this report

Based on technology, the polymerase chain reaction (PCR) segment accounted for the largest share of the market in 2016 

On the basis of technology, the Companion Diagnostics Market is broadly segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next-generation sequencing (NGS), and other technologies. In 2016, the polymerase chain reaction (PCR) segment accounted for the largest share of this market and the next-generation sequencing (NGS) segment is expected to register the highest CAGR during the forecast period. The large share of the PCR segment is attributed to its ease of use and to the fact that it does not require many samples for biomarker identification.

Based on indication of Companion Diagnostics Market, the oncology segment held the largest market share in 2016 

Based on the indication, the global Companion Diagnostics Market is divided into oncology, infectious diseases, neurology, and other indications. The oncology segment is expected to account for the largest share of the global Companion Diagnostics Market by indication. It is also the fastest growing segment owing to the increasing cases of cancer cases across the globe and the rising number of clinical trials targeting cancer biomarkers for lung, breast, and prostate cancers.

Download PDF Brochure:

Based on products & services, the assay kits & reagents segment held the largest market share in 2016 

On the basis of products & services, the market is segmented into assay kits, reagents, and software & services. The assay kits & reagents segment is accounted for largest share of this market in 2016. The large share of this segment can primarily be attributed to its wide range of applications in varied technology platforms. Companion diagnostic assays help eliminate the risk of severe side effects of non-targeted therapies on patients.

Based on end user, the pharmaceutical & biopharmaceutical companies segment held the largest market share in 2016 

By end user, the market is segmented into pharmaceutical & biopharmaceutical companies, reference laboratories, and other end users. The pharmaceutical and biopharmaceutical companies segment is accounted for the largest share of this market in 2016. This end-user segment is also expected to register the highest CAGR during the forecast period. This is due to the wide use of companion diagnostic kits among pharmaceutical and biopharmaceutical companies, due to their benefits such as high efficiency (the kits enable the selection of the most suitable candidates for clinical trials) and cost reduction.

Talk To Our Research Analysts:

North America dominated the market in 2016 

North America accounted for the largest share of the market in 2016, followed by Europe. The large share of the North American market is attributed to the increasing technological advancements aimed at developing companion diagnostic tests for new indications such as neurology, infectious diseases, and so on. The Asia-Pacific region is expected to register the highest CAGR over the next five years. The need for tailored therapeutics for the region's growing geriatric population; increasing number of hospitals and diagnostics laboratories; and growing prevalence of life-threatening diseases such as cancer and neurology diseases among others are driving the growth of the Companion Diagnostics Market.

The key players in the global Companion Diagnostics Market include Roche Diagnostics (Switzerland), Agilent Technologies, Inc. (U.S.), QIAGEN N.V. (Netherlands), and Abbott Laboratories Inc. (U.S.).

Browse Related Reports: 

BIOMARKER MARKET by Product (Consumables, Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, Cardiovascular Disorders), Application (Diagnostics Development, Drug Discovery and Development, Disease-Risk) - Global Forecast to 2021

IN VITRO DIAGNOSTICS/IVD MARKET by Product (Instruments, Reagents, Software), Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology), Application (Diabetes, Oncology, Cardiology, Nephrology, Infectious Diseases) - Forecast to 2021

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets' flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Mr. Rohan
701 Pike Street
Suite 2175, Seattle,
WA 98101, United States
Tel: +1-888-600-6441

Connect with us on LinkedIn @

SOURCE MarketsandMarkets


More From BioPortfolio on "Companion Diagnostics Market to Reach USD 6.51 Billion by 2022"

Quick Search

Relevant Topics

Polymerase Chain Reaction (PCR)
PCR (Polymerase Chain Reaction) uses the ability of DNA polymerase (enzymes that create DNA molecules by assembling nucleotides, the building blocks of DNA. These enzymes are essential to DNA replication and usually work in pairs to create two ident...

Breast Cancer
Track and monitor developments in breast cancer research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on breast cancer and follow companies active in the development of breast cancer tr...

Gilotrif (afatinib)
GILOTRIF (afatinib) is a kinase inhibitor indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L8...